This article discusses the use of a PET radiopharmaceutical called 68Ga-Trivehexin to target the "cancer integrin" αvβ6, which is highly expressed in various carcinomas. The study presents a case of a male patient with both metastatic head-and-neck cancer and pancreatic cancer, which were detected using 68Ga-Trivehexin PET/CT imaging. The imaging revealed intense uptake in the cerebellopontine angle, indicating a brain metastasis, as well as metastases in other areas. The authors conclude that 68Ga-Trivehexin PET/CT can effectively detect αvβ6-integrin expressing tumors and their metastases. [Extracted from the article]